Therapeutic drug monitoring (TDM): Anti-drug antibodies & drug levels In the era of treat-to-target approach and precision medicine, TDM, which consists of measuring drug levels and anti-drug antibodies (ADAs), is increasingly gaining attention [135]
Due to its mechanistic relevance, it is often discussed alongside broader investigations into metabolic signaling, mitochondrial function, and aging-related research models
The countries covered in the glutathione market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, Israel, Egypt, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
ARPC1A correlates with poor prognosis in prostate cancer and is up-regulated by glutamine metabolism to promote tumor cell migration, invasion and cytoskeletal changes